Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Roflumilast solid dispersoid and preparation method thereof as well as roflumilast preparation

A technology of solid dispersion and roflumilast, which is applied in the direction of medical preparations of non-active ingredients, pharmaceutical formulas, active ingredients of heterocyclic compounds, etc., can solve the problems of low bioavailability and slow dissolution rate, and achieve bioavailability high degree of effect

Active Publication Date: 2015-04-01
BEIJING COLLAB PHARMA
View PDF4 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Since roflumilast is a BCS2 drug, it is an extremely difficult to dissolve drug, so there are problems such as slow dissolution rate and low bioavailability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Roflumilast solid dispersoid and preparation method thereof as well as roflumilast preparation
  • Roflumilast solid dispersoid and preparation method thereof as well as roflumilast preparation
  • Roflumilast solid dispersoid and preparation method thereof as well as roflumilast preparation

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0040] The invention provides a preparation method of roflumilast solid dispersion, comprising the following steps:

[0041] a), the carrier is heated and melted to obtain a carrier melt;

[0042] The carrier is copovidone, poloxamer or polyethylene glycol;

[0043] b), the carrier melt is mixed with Roflumilast;

[0044] c), mixing the obtained mixture, cooling and crushing to obtain a solid dispersion of roflumilast.

[0045] In the present invention, the carrier is first heated and melted to obtain a carrier melt. The carrier is copovidone, poloxamer or polyethylene glycol.

[0046] The carrier melt and roflumilast are then mixed. The mass ratio of the carrier to roflumilast is preferably 3-10:1. The mixing method of the carrier melt and roflumilast is preferably stirring.

[0047] In some embodiments of the present invention, the solubilizer is preferably added during the mixing process of the carrier melt and roflumilast, and the process is: mixing the carrier melt,...

Embodiment 1

[0072] Preparation of Roflumilast Solid Dispersion

[0073] 5g copovidone (S-630) was heated and melted to obtain a melt. Add 1 g of roflumilast to the melt, stir to dissolve. The copovidone melt dissolved with roflumilast was poured on an iron plate at -20°C and cooled rapidly. The obtained solid was cooled and pulverized and passed through an 80-mesh sieve to obtain a solid dispersion of roflumilast.

[0074] Carry out DSC scanning and X-ray powder diffraction analysis to the above-mentioned obtained roflumilast solid dispersion, get copovidone-roflumilast physical mixture, pure copovidone and pure roflumilast parallel determination simultaneously, the result Such as figure 1 and figure 2 as shown, figure 1 It is the DSC scanning figure of the roflumilast solid dispersion prepared in Example 1 of the present invention, wherein A is pure copovidone, B is pure roflumilast, C is roflumilast solid dispersion, and D is copolymerization Vitone-roflumilast physical mixture; ...

Embodiment 2

[0077] Preparation of Roflumilast Solid Dispersion

[0078] 5g copovidone (S-630) was heated and melted to obtain a melt. Add 100 mg of polyoxyethylene hydrogenated castor oil (RH-40) to the melt, stir to dissolve, then add 1 g of roflumilast, and stir to dissolve. The copovidone melt dissolved with polyoxyethylene hydrogenated castor oil and roflumilast was poured on an iron plate at -20°C, and cooled rapidly. The obtained solid was cooled and pulverized and passed through an 80-mesh sieve to obtain a solid dispersion of roflumilast.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The application belongs to the field of medicines, and in particular relates to a roflumilast solid dispersoid and a preparation method thereof as well as a roflumilast preparation. The roflumilast solid dispersoid provided by the application comprises the following components in parts by weight: 1 part of roflumilast and 3-10 parts of a carrier, wherein the carrier is copovidone, poloxamer or polyethylene glycol. The roflumilast preparation provided by the invention comprises the following components in parts by weight: 0.4-12 parts of a solid dispersoid and 5-95 parts of a filling agent. Experiment results show that the 30-minute dissolution rate of the roflumilast solid dispersoid provided by the application is more than 96%; and the 30-minute dissolution rate of the roflumilast preparation provided by the invention is more than 98%, and the biological availability is more than 75%.

Description

technical field [0001] The invention belongs to the field of medicines, and in particular relates to a roflumilast solid dispersion, a preparation method thereof and a roflumilast preparation. Background technique [0002] Chronic obstructive pulmonary disease (COPD) is a chronic bronchitis or emphysema characterized by airflow obstruction, which can further develop into a common chronic disease of pulmonary heart disease and respiratory failure, with high morbidity and mortality. [0003] The exact etiology of COPD is unclear, but it is generally believed that factors related to the occurrence of chronic bronchitis and obstructive emphysema may be involved in the pathogenesis of COPD. The pathogenic factors that have been found can be roughly divided into two categories: environmental factors and individual susceptibility factors. Environmental factors include smoking, inhalation of dust and chemicals, air pollution, respiratory infections, etc. Individual predisposing fa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K31/44A61K47/32A61K47/10A61P11/00
Inventor 张永强王珂赵大龙邹德超
Owner BEIJING COLLAB PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com